Cytodyn is on a planned, focused, strategic course toward development and nothing I say is going to alter that, however if I were Cyrus I would look for a quick path to results and by extension higher share price to fund all the potential indications. For a time I thought sepsis could deliver quick results, however outcomes are heavily influenced by treatment protocols and how quickly the clinicians activate code sepsis and start pushing IV fluid bolus, antibiotics etc. There is always a chance you get unlucky by random assignment with differential intervention efforts. The priority is to act quickly and that also works against patient consent. The neuro-degeneration link by CTmedic showing cytokine cascade, and impact on impaired autophagy via CCR5 reminds me of a potential target with ALS that has been mentioned on this board. With no cure and a well recognized and relatively rapid decline in patient function, the standard of care IS to be in a clinical trial…these patients are clamoring for ANYTHING that might work. I know the physician who developed the rating scale (ALSFRS) taken with each visit so you can create an outcome measure off a standard clinical assessment that is used on all of these patients virtually everywhere. Patients tend to funnel to a clinic with a neurologist who specializes, so you can target a smaller number of trial sites, lowering study start up costs. With a safe drug profile you would likely enroll patients quickly. With any success you would also unequivocally open the neurodegenerative disease book for further development. HIV, NASH, Cancer, ( cue the King of Popiel: “but wait, there’s more”…) Alzheimer’s, Stroke, etc.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119763/